Erytech Pharma SA (ERYP.OQ)

About

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The... (more)

Buy/Sell

» Analyst Consensus

Overall

No Ratios Available.

Financials

	ERYP.OQ	Industry	Sector
P/E (TTM):	--	188.22	33.60
EPS (TTM):	--	--	--
ROI:	--	-0.74	13.19
ROE:	--	-2.80	15.00

Latest News about ERYP.OQ

BRIEF-Erytech To Present Results From Phase I Trial Of Eryaspase In All And New Pre Clinical Data At Aacr 2018

* ERYTECH TO PRESENT RESULTS FROM PHASE I TRIAL OF ERYASPASE IN ALL AND NEW PRE-CLINICAL DATA AT AACR 2018 Source text for Eikon: Further company coverage:

Apr 12 2018

BRIEF-Oncodesign Concludes A Partnership With Erytech In Oncology

* ONCODESIGN CONCLUDES A LONG TERM SERVICE-BASED PARTNERSHIP WITH ERYTECH IN ONCOLOGY

Mar 27 2018

BRIEF-Erytech FY Net Loss Widens To 33.5 Million Euros

* REPORTED ON MONDAY FY NET LOSS 33.5 MILLION EUROS, COMPARED TO 21.9 MILLION EUROS IN 2016

Mar 13 2018

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES

Nov 10 2017

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

Nov 10 2017

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

Nov 07 2017

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍ - sec filing

Nov 06 2017

» More ERYP.OQ News